Navigation Links
DNA Sequencing: Technologies, Markets and Companies - 2013 Report
Date:6/18/2013

DUBLIN, June 18, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/5g3rx5/dna_sequencing) has announced the addition of the report "DNA Sequencing - Technologies, Markets and Companies" to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

This report briefly reviews basics of human genome variations, development of sequencing technologies, and their applications. Current large and small sequencers are described as well as companies developing them. Various applications of sequencing are described including those for genetics, medical diagnostics, drug discovery and cancer. Next generation sequencing technologies, both second and third generations, are reviewed. Companies developing software for analysis of sequencing data are also included. Selected academic institutes conducting research in sequencing are also listed.

The current market is mostly for research applications and future markets will be other applications related to healthcare. The value of the DNA sequencer market in 2012 is described with estimates for 2017 and 2022. Various methods and factors on which market estimates depend are described briefly. Markets are tabulated according to geographical areas as well as applications. Small sequencers form the basis of SWOT (strengths, weaknesses, opportunities, threats) analysis. Several marketing strategies have been outlined.

The report includes profiles of 108 companies involved in sequencing and their 106 collaborations. The report text is supplemented by 36 tables, 12 figures and 320 selected references to the literature.

Key Topics Covered:

Executive Summary'/>"/>

SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
4. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
5. Animal Biotechnology - Technologies, Markets and Companies
6. Gene Therapy - Technologies, Markets and Companies
7. Biomarkers - Technologies, Markets and Companies
8. Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Cytogenetics - Technologies, Markets and Companies
10. Cell Therapy - Technologies, Markets and Companies
11. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report  "Alzheimer Disease ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... in management. With nearly 8 million sufferers ... markets of the world and anticipated increases ...
(Date:5/28/2015)... May 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ... Genetics Market by Products, by Testing services - Global ... The global animal genetics market is estimated to ... at a CAGR of 8-9% during the forecast period ... mainly driven by increasing animal protein consumption, increasing adoption ...
(Date:5/28/2015)... Calif. , May 28, 2015 ... today announced a study published in Ultrasound ... Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test (NIPT) ... first trimester. A study based ... complete molar pregnancies occur in about 1 in ...
(Date:5/28/2015)... MIAMI BEACH, Fla. , May 28, 2015 /PRNewswire/ ... data supporting the anti-cancer potential of its growth hormone-releasing ... presentation at the 2015 ASCO Annual Meeting. The ... the target for Biscayne,s anti-cancer GHRH blockers, is present ... receptor status. These findings suggest that GHRH antagonists could ...
Breaking Biology Technology:Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 2Global Alzheimer Disease Report 2015-2024 - New Drugs, Markets and Companies 3Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3
... Genoptix, Inc.,(Nasdaq: GXDX ), a specialized ... the BIOCOM Investor Conference 2008,scheduled to take place ... on October,26-28, 2008., Dr. Tina Nova, President ... on Monday, October 27, beginning at approximately 9:30 ...
... ... - Results Presented at the 20th EORTC-NCI-AACR Symposium on Molecular ... Targets and Cancer Therapeutics -, GENEVA and SAN FRANCISCO, ... new data from an,ongoing Phase 1-2 clinical trial demonstrating that the Company,s novel,androgen ...
... Presented at 20th EORTC-NCI-AACR Symposium -, ... 22 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced positive incremental data from,its randomized, ... in patients,with metastatic colorectal cancer (CRC). The ...
Cached Biology Technology:Genoptix Announces Participation at the BIOCOM Investor Conference 2008 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 2Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 3Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 4Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 5
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Testing people for heart disease might be just a finger ... by a team of researchers from Harvard and Northeastern universities ... FASEB Journal ( http://www.fasebj.org ), they describe how ... needed to build vascular tissue, called endothelial progenitor cells, using ...
... Boston, MA June 1, 2009 REGiMMUNE ... in combination with a low-dose of Sirolimus, demonstrated enhanced ... transplantation and acute Graft-versus-Host disease (GvHD). This data ... Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) ...
... species are likely to respond to climate change. Most ... and the interactions between species, in the interest of ... BioScience , by Eric Post of Pennsylvania State University ... avoided. Their approach, which relies on multi-stage analyses of ...
Cached Biology News:New device detects heart disease using less than one drop of blood 2REGiMMUNE presents enhanced efficacy data in preclinical transplantation models 2
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
... a post-translational modification that plays an ... immune regulation, inflammation, cell-to-cell adhesion, and ... two lectin based Glycoprotein Isolation Kits, ... Agglutinin (WGA), that allow isolation of ...
... The LS series of laser scanners ... Gene Expression Suite solution. ,Gene expression ... other requirements essential to the advancement ... giving rise to novel microarray formats and ...
...
Biology Products: